Cargando…
Do single‐arm trials have a role in drug development plans incorporating randomised trials?
Often, single‐arm trials are used in phase II to gather the first evidence of an oncological drug's efficacy, with drug activity determined through tumour response using the RECIST criterion. Provided the null hypothesis of ‘insufficient drug activity’ is rejected, the next step could be a rand...
Autores principales: | Grayling, Michael J., Mander, Adrian P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855632/ https://www.ncbi.nlm.nih.gov/pubmed/26609689 http://dx.doi.org/10.1002/pst.1726 |
Ejemplares similares
-
Escalation strategies for combination therapy Phase I trials
por: Sweeting, Michael J, et al.
Publicado: (2012) -
HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022) -
Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported Adequately
por: Grayling, Michael J., et al.
Publicado: (2021) -
Re-formulating Gehan’s design as a flexible two-stage single-arm trial
por: Grayling, Michael J., et al.
Publicado: (2019) -
A stochastically curtailed two-arm randomised phase II trial design for binary outcomes
por: Law, Martin, et al.
Publicado: (2021)